AtriCure (NASDAQ:ATRC) Given New $62.00 Price Target at JPMorgan Chase & Co.

Key Points

• JPMorgan raised its AtriCure price target to $62 from $36 but maintained a neutral rating; the target implied 4.2% downside from the prior close.
• AtriCure beat quarterly estimates, reporting earnings of $0.17 per share versus consensus for a $0.06 loss, and revenue of $154.45 million versus $151.05 million expected.
• Analyst views remain mixed: six rate the stock Buy, five Hold and one Sell, with an average price target of $60.60. Shares traded at $64.72 on Wednesday, near their 52-week high of $65.09.

AtriCure (NASDAQ:ATRC - Get Free Report) had its price objective upped by JPMorgan Chase & Co. from $36.00 to $62.00 in a report released on Wednesday, Benzinga reports. The firm presently has a "neutral" rating on the medical device company's stock. JPMorgan Chase & Co.'s price target suggests a potential downside of 4.20% from the stock's previous close.

A number of other analysts have also recently commented on ATRC. Stifel Nicolaus set a $65.00 price objective on AtriCure in a research report on Thursday, September 17th. Raymond James Financial set a $52.00 price target on shares of AtriCure in a report on Tuesday, July 21st. Zacks Research cut shares of AtriCure from a "strong-buy" rating to a "hold" rating in a research report on Monday, August 24th. Needham & Company LLC lifted their target price on shares of AtriCure from $64.00 to $70.00 and gave the company a "buy" rating in a research report on Wednesday. Finally, BTIG Research boosted their target price on shares of AtriCure from $63.00 to $70.00 and gave the stock a "buy" rating in a research note on Wednesday. Six analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $60.60.

AtriCure Stock Performance

ATRC traded up $4.31 during trading on Wednesday, reaching $64.72. 712,495 shares of the company's stock were exchanged, compared to its average volume of 871,546. The company's fifty day simple moving average is $56.03 and its 200-day simple moving average is $38.40. The stock has a market capitalization of $3.29 billion, a P/E ratio of 306.12 and a beta of 1.23. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19. AtriCure has a 1 year low of $25.36 and a 1 year high of $65.09.

AtriCure (NASDAQ:ATRC - Get Free Report) last issued its earnings results on Tuesday, November 3rd. The medical device company reported $0.17 EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.23. The firm had revenue of $154.45 million for the quarter, compared to the consensus estimate of $151.05 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%. As a group, research analysts predict that AtriCure will post 0.29 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Regina Groves sold 5,313 shares of the stock in a transaction on Friday, September 11th. The stock was sold at an average price of $54.22, for a total value of $288,070.86. Following the completion of the transaction, the director directly owned 34,546 shares of the company's stock, valued at approximately $1,873,084.12. This represents a 13.33% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Salvatore Privitera sold 4,519 shares of the firm's stock in a transaction on Wednesday, September 23rd. The shares were sold at an average price of $60.00, for a total value of $271,140.00. Following the completion of the transaction, the insider owned 142,745 shares in the company, valued at $8,564,700. The trade was a 3.07% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 30,622 shares of company stock worth $1,626,003. 4.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On AtriCure

Hedge funds and other institutional investors have recently modified their holdings of the business. Man Group plc acquired a new stake in AtriCure during the second quarter worth $684,000. Bank of America Corp DE boosted its position in AtriCure by 13.7% in the 1st quarter. Bank of America Corp DE now owns 768,561 shares of the medical device company's stock valued at $21,927,000 after buying an additional 92,830 shares during the period. WINTON GROUP Ltd purchased a new stake in AtriCure during the 2nd quarter worth about $1,002,000. The Manufacturers Life Insurance Company purchased a new position in AtriCure in the second quarter worth approximately $699,000. Finally, Jupiter Topco LLC purchased a new position in AtriCure in the second quarter valued at $640,000. 99.11% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about AtriCure

Here are the key news stories impacting AtriCure this week:

• Positive Sentiment: AtriCure reported Q3 revenue of $154.45 million, above the $151.05 million consensus, and earnings of $0.17 per share, beating estimates. AtriCure beats Q3 earnings and revenue estimates
• Positive Sentiment: Management forecast 2026 revenue of $606 million to $610 million and adjusted EBITDA of $91 million to $94 million, supporting a constructive growth outlook. The revenue range is close to the cited FactSet estimate of $606.2 million. AtriCure projects 2026 adjusted EBITDA
• Positive Sentiment: Analyst sentiment improved after the results: Piper Sandler reaffirmed its overweight rating and raised its target to $70 from $60, while Needham raised its target to $70 from $64 and kept a buy rating. BTIG also lifted its target to $70. Analysts boost forecasts after Q3 results BTIG raises AtriCure price target
• Neutral Sentiment: The company is targeting completion of enrollment in its BoxX-NoAF study by year-end; the milestone may inform future clinical and commercial prospects, but no new results were reported. AtriCure study enrollment and outlook

AtriCure Company Profile

AtriCure, Inc is a medical device company that develops and sells products for the surgical treatment of atrial fibrillation (AFib) and related conditions. Its technologies are designed to support cardiac surgeons and electrophysiologists performing tissue ablation, left atrial appendage management and other procedures intended to restore or maintain normal heart rhythm.

The company's product portfolio includes the AtriClip device, which is used to exclude the left atrial appendage, along with surgical ablation systems such as the Isolator Synergy clamps and cryoablation products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.